Last updated: February 20, 2026
Who are the primary suppliers of divalproex sodium?
Multiple companies manufacture and distribute divalproex sodium, a widely used antiepileptic drug, primarily under generic and branded formulations.
Major Manufacturers and Suppliers
| Company Name |
Product Type |
Key Markets |
Production Capacity |
Notes |
| Teva Pharmaceuticals |
Generic divalproex sodium |
Global |
High |
Largest generic manufacturer; ISO-certified facilities |
| Mylan (now part of Viatris) |
Generic divalproex sodium |
Global |
High |
Significant presence in North America and Europe |
| Sun Pharmaceutical |
Generic divalproex sodium |
Asia, Europe, North America |
Moderate |
Operates multiple manufacturing sites |
| Actavis (now Teva) |
Branded / Generic |
North America, Europe |
High |
Acquired by Teva in recent years |
| Lupin Limited |
Generic divalproex sodium |
India, Asia, Africa |
Moderate |
Focus on emerging markets |
| Hetero Labs |
Generic divalproex sodium |
India, Middle East, Asia |
Moderate |
Significant regional supplier |
| BGP Pharmaceuticals |
API (Active Pharmaceutical Ingredient) |
Asia |
Variable |
Produces the API for several generics |
Branded Versions
- Depakote (AbbVie/AbbVie-related entities): Used mainly in North America, produced by AbbVie, although manufacturing has transitioned over the years.
- Depakote ER: Extended-release formulation made by original developers, now available under multiple generic brands.
Manufacturing Considerations
- The API for divalproex sodium is produced predominantly in India, China, and Europe.
- Quality standards adhere to Good Manufacturing Practices (GMP), with facilities certified by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or equivalent agencies.
- Production capacity varies widely; the leading generics firms operate multiple large-volume facilities.
Supply Chain Dynamics
- Suppliers are subject to regulatory approvals, which influence manufacturing timelines.
- Patent expiry for originator products like Depakote in various regions has led to increased generic competition.
- Supply chain disruptions may arise from raw material shortages, regulatory issues, or geopolitical factors.
Key Points
- Teva and Mylan are dominant global suppliers, accounting for a major part of the therapeutic market share.
- Indian pharmaceutical companies, Lupin and Hetero, are critical for regional supply, especially in emerging markets.
- API production primarily happens in India and China; finished formulations are assembled worldwide.
- The generic market for divalproex sodium remains highly competitive owing to patent expirations and cost pressures.
Key Takeaways
- The global supply of divalproex sodium depends substantially on Indian and Chinese API manufacturers.
- The leading generic manufacturers, Teva and Mylan, control significant market shares.
- Regional suppliers like Lupin and Hetero serve local markets with moderate capacities.
- Supply chain and regulatory compliance are critical for uninterrupted drug availability.
- Branded formulations like Depakote have reduced market share with the rise of generics.
FAQs
1. Who are the largest producers of divalproex sodium API?
Indian companies Lupin and Hetero are major API producers, with production facilities in India, China, and other regions.
2. Are there regional differences in suppliers?
Yes. North American and European markets predominantly use Teva, Mylan, and AbbVie; Asian markets rely heavily on Indian manufacturers.
3. Has patent expiration increased generic options?
Yes. Patent expiry in various jurisdictions has led to increased competition and a broader supplier base.
4. What standards govern the manufacturing of divalproex sodium?
Manufacturers must comply with GMP standards set by regulatory authorities like the FDA and EMA.
5. Are supply chain disruptions common?
Disruptions can occur due to raw material shortages, regulatory delays, or geopolitical issues, impacting API availability and formulation supply.
References
[1] U.S. Food and Drug Administration. (2022). Drug Approvals and Facility Certifications.
[2] European Medicines Agency. (2022). API Manufacturing and Quality Standards.
[3] IMS Health (IQVIA). (2022). Pharmaceutical Market Analysis Reports.
[4] Indian Pharmaceutical Industry Association. (2021). Market Data and Regulatory Overview.
